ZA200706338B - 1-H-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as FAK, KDR and TIE2 Kinase modulators for the treatment of cancer - Google Patents

1-H-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as FAK, KDR and TIE2 Kinase modulators for the treatment of cancer

Info

Publication number
ZA200706338B
ZA200706338B ZA200706338A ZA200706338A ZA200706338B ZA 200706338 B ZA200706338 B ZA 200706338B ZA 200706338 A ZA200706338 A ZA 200706338A ZA 200706338 A ZA200706338 A ZA 200706338A ZA 200706338 B ZA200706338 B ZA 200706338B
Authority
ZA
South Africa
Prior art keywords
carboxamides
fak
kdr
pyrrole
imidazole
Prior art date
Application number
ZA200706338A
Other languages
English (en)
Inventor
Ronan Baptiste
Halley Frank
Souaille Catherine
Viviani Fabrice
El-Ahmad Youssef
Bacque Eric
Tabart Michel
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ZA200706338B publication Critical patent/ZA200706338B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA200706338A 2005-02-03 2006-02-01 1-H-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as FAK, KDR and TIE2 Kinase modulators for the treatment of cancer ZA200706338B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501092A FR2881426B1 (fr) 2005-02-03 2005-02-03 Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation

Publications (1)

Publication Number Publication Date
ZA200706338B true ZA200706338B (en) 2008-11-26

Family

ID=34954950

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706338A ZA200706338B (en) 2005-02-03 2006-02-01 1-H-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as FAK, KDR and TIE2 Kinase modulators for the treatment of cancer

Country Status (20)

Country Link
US (1) US7560571B2 (xx)
EP (1) EP1856043B1 (xx)
JP (1) JP2008528661A (xx)
KR (1) KR20070103420A (xx)
CN (1) CN101133023A (xx)
AR (1) AR053540A1 (xx)
AT (1) ATE512133T1 (xx)
AU (1) AU2006210343A1 (xx)
BR (1) BRPI0606761A2 (xx)
CA (1) CA2595987A1 (xx)
EA (1) EA012267B1 (xx)
FR (1) FR2881426B1 (xx)
IL (1) IL184710A0 (xx)
MA (1) MA29264B1 (xx)
MX (1) MX2007009442A (xx)
NO (1) NO20074414L (xx)
TW (1) TW200640857A (xx)
UY (1) UY29361A1 (xx)
WO (1) WO2006082309A1 (xx)
ZA (1) ZA200706338B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881742B1 (fr) 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
AU2007235237B2 (en) 2006-04-11 2011-08-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP3069721A1 (en) * 2008-08-15 2016-09-21 Nivalis Therapeutics, Inc. Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
DK2315590T3 (da) * 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
EP2318007B1 (en) 2008-08-15 2013-01-23 N30 Pharmaceuticals, Inc. Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
CN102775354A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 一种合成4-芳基-5-羧酸咪唑及其酯的工艺方法
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
US9828364B2 (en) 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
EA034561B1 (ru) 2015-12-16 2020-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
AU2002366440A1 (en) * 2001-09-27 2003-09-09 Smithkline Beecham Corporation Chemical compounds
US20040138269A1 (en) * 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
CA2521962A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Anti-diabetic agents
DE10354060A1 (de) 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
FR2881742B1 (fr) 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation

Also Published As

Publication number Publication date
US7560571B2 (en) 2009-07-14
US20080045542A1 (en) 2008-02-21
ATE512133T1 (de) 2011-06-15
MX2007009442A (es) 2008-03-10
TW200640857A (en) 2006-12-01
EA200701648A1 (ru) 2008-02-28
AU2006210343A1 (en) 2006-08-10
UY29361A1 (es) 2006-08-31
BRPI0606761A2 (pt) 2009-07-14
MA29264B1 (fr) 2008-02-01
EP1856043B1 (fr) 2011-06-08
FR2881426A1 (fr) 2006-08-04
CN101133023A (zh) 2008-02-27
KR20070103420A (ko) 2007-10-23
EA012267B1 (ru) 2009-08-28
IL184710A0 (en) 2007-12-03
WO2006082309A1 (fr) 2006-08-10
EP1856043A1 (fr) 2007-11-21
CA2595987A1 (fr) 2006-08-10
JP2008528661A (ja) 2008-07-31
NO20074414L (no) 2007-11-05
AR053540A1 (es) 2007-05-09
FR2881426B1 (fr) 2007-03-30

Similar Documents

Publication Publication Date Title
IL184710A0 (en) 1-h-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as fak, kdr and tie2 kinase modulators for the treatment of cancer
HK1127489A1 (en) Pyridiazinone derivatives for the treatment of tumours
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
IL188430A0 (en) Treatment of tumors
IL188746A0 (en) Treatment of cancer
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
HK1117780A1 (en) Compounds and methods for the treatment of cancer
PT1945243E (pt) Utilização da calcitonina para o tratamento da ar
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
EP2207555A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OR MITIGATION OF OEDEMES, AND METHODS OF USE THEREOF
GB0517387D0 (en) Combinations for the treatment of cancer
HK1151971A1 (en) Compounds for use in the treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0619816D0 (en) Novel interferon-alpha constructs for use in the treatment of cancer
EP1904088A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
EP1917041A4 (en) USE OF FRUCTOSE-BASED THERAPIES FOR CANCER TREATMENT
IL226362A0 (en) compounds, and methods for treating cancer
GB0520067D0 (en) Treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB0525535D0 (en) Tumour treatment
ZA200706871B (en) Treatment of metastasized tumors